RETRACTED: A vulnerable young adult using cannabis for therapeutic purposes despite emerging psychosis
Jill M. Williams, Mary Barna Bridgeman, Lisa Laitman
Psychiatry Research Case Reports July 23, 2022 Retracted DOI: 10.1016/j.psycr.2022.100037 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 20-year-old student prescribed cannabis for therapeutic purposes in the context of an emerging psychotic illness |
| Intervention | Cannabis for therapeutic purposes (CTP) |
| Topics | Cannabis |
| Key findings | The authors describe a 20-year-old student prescribed cannabis for therapeutic purposes who was hospitalized for a psychotic episode, with CTP described as a risk factor complicating care. They attribute concerns to emerging psychosis, escalating cannabis use, and lack of coordination among providers, and argue that without federal oversight, inconsistent screening, consenting, and authorization practices will continue. |
Abstract
There is widespread support of cannabis for therapeutic purposes (CTP) despite lack of federal oversight and inconsistencies in screening, consenting, and authorizing use. Young people may have increased vulnerability to adverse effects including psychosis, substance use disorder, reduced academic achievement or other symptoms. We describe a case of a 20 year old who was prescribed CTP in the context of an emerging psychotic illness. The student was hospitalized for a psychotic episode and CTP a risk factor that complicated care. Use of CTP in this patient was concerning for several reasons, including emergence of psychosis, escalating cannabis use, as well as the lack of coordination among health care providers. This case illustrates the complexity of evaluating and treating high-risk youth; every precaution should be taken to prevent harm, reduce pathology and improve functioning. Without federal regulation and oversight, variable guidance for screening, consenting, authorizing and procuring CTP will unfortunately continue.
Comparable studies
Other case reports and case series on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Hallucinogen persisting perception disorder after psilocybin consumption: a case study 18-year-old man with HPPD after mixed psilocybin and cannabis intoxication | 2005 | Case study | n = 1 |
| Cannabis‐induced Koro in Americans American men aged 22-26 with years of cannabis experience who reported negative... | 2001 | Case series | n = 3 |
| “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs Healthy 30-year-old male | 2018 | Case study | n = 1 |
| Hallucinogen persisting perception disorder: A literature review and three case reports Patients with hallucinogen persisting perception disorder | 2018 | Case series | n = 3 |
| Cannabis Psychosis in Young Psychiatric Inpatients Consecutive psychiatric hospital admissions of patients aged 35 and under | 1986 | Case study | n = 25 |